Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY(®)) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study

Fremanezumab, a fully humanized IgG2Δa/kappa monoclonal antibody, selectively targets the calcitonin-gene-related peptide (CGRP) and prevents it from binding to the CGRP receptor. The safety, tolerability, pharmacokinetics (PK), and efficacy of fremanezumab for treating migraines administered as a o...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Aksana, Cohen-Barak, Orit, Radivojevic, Andrijana, Fiedler-Kelly, Jill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225049/
https://www.ncbi.nlm.nih.gov/pubmed/34074002
http://dx.doi.org/10.3390/pharmaceutics13060785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225049/
https://www.ncbi.nlm.nih.gov/pubmed/34074002
http://dx.doi.org/10.3390/pharmaceutics13060785

Ejemplares similares